hit counter

Lurasidone Improves Positive Symptoms of Schizophrenia More Than Negative

MHD featured image for Lurasidone PANSS Domains: Positive Symptoms Lead, Negative Lag.

Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …

Read more

Striatal Dopamine Drops From Psychosis to Schizophrenia Remission

Photoreal illustration of a brain with the striatum highlighted and dopamine synthesis pathways visualized, representing longitudinal PET imaging in schizophrenia.

The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story, and most of its supporting evidence has been cross-sectional. A 2026 longitudinal PET study by Schulz and colleagues followed the same 28 patients across psychosis and early remission.1 Research Highlights The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story. Cross-sectional 18F-DOPA PET …

Read more

Black Americans Diagnosed with Schizophrenia 2.42x the Rate of White Americans: More Negative Symptoms

Photoreal illustration representing racial stress and mental health, with conceptual imagery of contemplation, identity, and cognitive pathways.

Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42 times the rate of White Americans, and they also score higher on negative-symptom measures than White patients carrying the same diagnosis.2 A 2026 paper by Spann and colleagues asks why. Research Highlights Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42x the rate of White Americans, …

Read more

Lupus Psychosis: 4.5% Prevalence and Antibody Predictors

Stylized illustration of autoantibodies and immune complexes crossing a disrupted blood-brain barrier, evoking the immune-mediated mechanism by which lupus produces psychosis.

Psychosis is one of 19 neuropsychiatric syndromes the American College of Rheumatology recognizes as attributable to systemic lupus erythematosus (SLE), an autoimmune disease that disproportionately affects young women.2 A 2026 systematic review and meta-analysis from Parperis and colleagues in Lupus pooled 65 studies and 31,495 patients.1 The synthesis matters less for the headline 4.5% prevalence …

Read more

Quetiapine-Induced Psychosis: A Rare Adverse Effect (2024 Case Report)

Quetiapine, a second-generation antipsychotic medication, is renowned for its efficacy in managing a spectrum of psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder (MDD). Despite its broad therapeutic utility and a generally favorable side effect profile, quetiapine’s role in rare instances of inducing psychotic symptoms warrants a closer examination. Highlights: Quetiapine’s Mechanism of …

Read more

Cannabis (Marijuana) Use & Psychosis: Does It Increase Risk? (2023 Evidence Review)

The relationship between cannabis (marijuana) use and psychosis has been a topic of considerable scientific interest and public health concern. With changing legal statuses and societal attitudes towards cannabis use in many countries, understanding this relationship is more critical than ever. Highlights: Systematic reviews and meta-analyses show a consistent association between cannabis use and increased …

Read more

Genetic Risk for Low Vitamin D Linked to Lower Social Motivation in First-Episode Psychosis (2024 Study)

Recent research reveals a notable association between vitamin D levels and the severity of negative symptoms in individuals with first-episode psychosis (FEP). A new study explored the genetic predisposition towards lower vitamin D levels and its impact on symptom severity in schizophrenia and related disorders. Highlights: Vitamin D & Psychosis Connection: Lower levels of vitamin …

Read more